Concomitant Irritable Bowel Syndrome Does Not Influence the Response to Antimicrobial Therapy in Patients with Functional Dyspepsia.

Ayesha ShahSaravana Ruban GurusamyTeressa HansenGavin CallaghanNicholas J TalleyNatasha KoloskiMarjorie M WalkerMichael P JonesMark MorrisonGerald J Holtmann

Published in: Digestive diseases and sciences (2021)

In FD patients, the response to antimicrobial therapy with rifaximin is not influenced by concomitant IBS symptoms.

Keyphrases

irritable bowel syndrome
end stage renal disease
staphylococcus aureus
newly diagnosed
ejection fraction
chronic kidney disease
stem cells
cell therapy